

For Health Professionals Who Care for People with Cancer

Inside This Issue:

Editor's Choice

New Programs

UBRAVCAFLV: Therapy of Advanced Breast Cancer using Capivasertib with Endocrine Therapy

GUPADT: Androgen Deprivation Therapy for Prostate Cancer

Expansion of Existing Programs

LYAVDBV: Treatment of Previously Untreated Stage III or IV Hodgkin Lymphoma

SMAVIPNI: Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab and Nivolumab

Filgrastim Biosimilar: Transition to NYPOZI as Default Biosimilar

Highlights of Protocol Changes

Cancer Drug Manual®

New: Avapritinib

Revised: Brentuximab Vedotin, Capivasertib, Docetaxel, Eribulin, Zanubrutinib

Retired: Nilutamide

Continuing Education

Family Practice Oncology Network

Benefit Drug List

New: UBRAVCAFLV, GUPADT, Brentuximab Vedotin (Pediatric)

Deleted: GUPLHRH, GUPLHRHA, GUPNSAA

New Protocols, PPPOs and Patient Handouts

BR UBRAVCAFLV **GU** GUPADT

REVISED Protocols, PPPOs and Patient Handouts

BR BRAJAC, BRAJACT, BRAJACTG, BRAJACTT, BRAJACTTG, BRAJACTW, BRAJDAC, BRAJDC, BRAJDCARBT, BRAJFEC, BRAJFECF, BRAJFECFDT, BRAJPEM, BRAJPNCT, BRAJTDC, BRAVPEM, BRAVPEM6, BRAVPGC, BRAVPP, BRAVPPN, BRAVSG, BRLAACD, BRLAACDT, BRLACPNAC, BRLACPNACG, BRLACTWAC, BRLACTWACG, BRLAPNAC, BRLAPNACG, BRLATACG, BRLATWAC, BRPCWTAC, BRPCTAC | **CN** CNMODPCV | **GI** GIAVDURPG, GIAVPEMPG, GIAVPG | **GU** UGUMCSPDD, GUPDOCADT | **LY** LYAVDBV | **SM** SMAJNIV, SMAJNIV4, SMAJPEM, SMAJPEM6, SMAVIPNI, SMNAPEM

Resources and Contact Information

Editor's Choice

New Programs

BC Cancer Provincial Systemic Therapy has approved the following new treatment programs effective 01 May 2025. Full details of all treatment programs are available in the Chemotherapy Protocols section of the BC Cancer website.

Breast

Therapy of Advanced Breast Cancer using Capivasertib with Fulvestrant (UBRAVCAFLV) – The BC Cancer Breast Tumour Group is introducing capivasertib in combination with endocrine therapy as a new treatment option for patients with hormone receptor positive, HER2-negative, locally advanced or metastatic breast cancer, following disease progression on or after endocrine therapy. Patients must have a confirmed PIK3CA, AKT1 or PTEN gene alteration.

Editor's Choice

Capivasertib is an orally administered kinase inhibitor that inhibits the AKT pathway, which plays a role in cancer cell growth and survival.

The combination is supported by results from the phase III CAPItello-291 trial, which showed significantly improved progression-free survival compared to fulvestrant alone.^{1,2} Common side effects of capivasertib include hyperglycemia, diarrhea and cutaneous reactions, which are generally considered as manageable with supportive care and dose adjustments.

BC Cancer Compassionate Access Program (CAP) approval is required prior to treatment.

The somatic NGS testing laboratory requisition form is available on the BC Cancer Chemotherapy protocols page. Please ensure the requisition includes clear instructions for the clerical team to fax the completed requisition form and correct pathology report to the appropriate pathology lab. This is necessary to guarantee correct specimen shipment. The turnaround time is 10 business days from the laboratory's receipt of the sample. The resulting report will be filed under "Molecular reports" or "External reports" and should be included in the CAP request.

Genitourinary

Androgen Deprivation Therapy (ADT) for Prostate Cancer (GUPADT) – The BC Cancer Genitourinary Tumour Group is introducing a new ADT protocol for treatment of prostate cancer, to simplify the prescriber ordering process. This new protocol amalgamates three previously separate protocols into a single protocol, namely GUPLHRH (LHRH agonists), GUPNSAA (antiandrogens) and GUPLHRHA (degarelix).

The change is intended to reduce complexity and improve efficiency while maintaining the same treatment options for patients. As part of this update, the three individual protocols (GUPLHRH, GUPNSAA, GUPLHRHA) will be retired. Note that nilutamide is no longer available in Canada and therefore it is not included in the new GUPADT protocol.

References:

1. Turner NC, Oliveira M, Howell SJ, et al; CAPItello-291 Study Group. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. *N Engl J Med*. 2023 Jun 1 ;388(220) :2058-2070.
2. Capivasertib (Truqap) CADTH Reimbursement Recommendation. *Canadian Journal of Health Technologies*. Sep 2024; 4(9):1-35.

Expansion of Existing Programs

BC Cancer Provincial Systemic Therapy has approved the expansion of the following treatment programs effective 01 May 2025.

Lymphoma

Treatment of Previously Untreated Stage III or IV Hodgkin Lymphoma with Doxorubicin, Vinblastine, Dacarbazine and Brentuximab Vedotin (LYAVDBV) – The BC Cancer Lymphoma Tumour Group is expanding the eligibility criteria to include stage III Hodgkin lymphoma patients. This change is due to five-year follow-up data from the phase III, multicentre randomised control trial, ECHELON-1, which showed a benefit in overall survival compared with doxorubicin, bleomycin, vinblastine and dacarbazine.^{1,2}

Editor's Choice

Skin & Melanoma

Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab and Nivolumab (SMAVIPNI) –

The BC Cancer Skin & Melanoma Tumour Group is removing the exclusion criteria of progression during or within 6 months of adjuvant PD-1 therapy. This change is due to a recent Canada's Drug Agency recommendation that ipilimumab in combination with nivolumab be reimbursed for first line treatment of advanced melanoma in patients who progress during or within 6 months of adjuvant PD-1 therapy.³

References:

1. Ansell S et al. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. N Engl J Med 2022;387(4):310-320.
2. Brentuximab vedotin (Adcetris) Canada's Drug Agency (CDA-AMC) Reimbursement Recommendation. Canadian Journal of Health Technologies Sep 2024; 4(9): 1-24.
3. Nivolumab plus ipilimumab Canada's Drug Agency (CDA-AMC) Reimbursement Recommendation. Canadian Journal of Health Technologies Jul 2024: 1-8.

Transition to NYPOZI as Default Filgrastim Biosimilar

Effective 01 May 2025, BC Cancer will transition to using NYPOZI as the default filgrastim biosimilar for outpatient use, for indications specified for PharmaCare coverage by the [PharmaCare Special Authority reimbursement criteria](#). NYPOZI has been listed by PharmaCare as a Limited Coverage benefit with the same criteria as other filgrastim biosimilars, GRASTOFIL and NIVESTYM since March 4, 2024.

BC Cancer protocols and pre-printed orders are not affected by this transition.

BC Cancer Cerner PowerPlans containing filgrastim orders will be updated to specify the NYPOZI brand at a later date in a coordinated effort with other Health Authorities.

Highlights of Protocol Changes

Effective 01 May 2025, the Breast Tumour Group is implementing updates to several protocols to reflect current best practices in febrile neutropenia prevention and management. Filgrastim is now mandatory in select protocols where the risk of febrile neutropenia is greater than 20%. In addition, other protocols now include updated language indicating that primary prophylaxis with filgrastim is not mandatory but may be considered for patients with specific risk factors. These changes aim to enhance patient safety and support individualized treatment decisions.

Please refer to the revised protocol section for a list of affected protocols and consult individual protocols for details.

Cancer Drug Manual[®]

All documents are available in the [Cancer Drug Manual[®]](#) on the BC Cancer website.

New Documents

Note that the following drug is not a BC Cancer Benefit Drug and requires application to the BC Cancer Compassionate Access Program (CAP). The corresponding Interim Monograph and Patient Handout are made available for reference only.

The **Avapritinib Interim Monograph** and **Patient Handout** have been developed with expert review provided by Dr. Donna Forrest (medical oncologist, BC Cancer Leukemia & BMT Tumour Group), Dr. Lynda Foltz (medical oncologist, BC Cancer Myeloid Tumour Group), and Robert Tillmanns (tumour group pharmacist, BC Cancer Provincial Pharmacy). Avapritinib is an orally administered kinase inhibitor that selectively targets KIT and platelet-derived growth factor receptor alpha (PDGFRA), with high potency against KIT D816V and PDGFRA D842V mutations. It is used in the treatment of advanced systemic mastocytosis. The usual dose is 200 mg PO once daily.

Highlights from these documents include:

- fluid retention (including periorbital/peripheral edema and pleural effusion) can occur; monitor for rapid weight gain or respiratory symptoms
- cognitive effects may present as a broad spectrum of symptoms including memory impairment, confusion, delirium, mental status changes or speech disturbance
- fatal cases of intracranial hemorrhage have been reported; avoid use in patients with platelet count of less than $50 \times 10^9/L$

Avapritinib has been added to the **Auxiliary Label List** and was evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

Revised Documents

Brentuximab Vedotin Monograph

Cautions: updated *Mutagenicity, Fertility, and Pregnancy*; deleted FDA pregnancy category

Supply and Storage: updated manufacturer/supplier to Seagen/Pfizer

Dosage Guidelines: updated pediatric dosing (Expert reviewer: Jennifer Kendrick, Clinical Pharmacy Specialist, BC Children's Hospital)

Capivasertib Monograph and Patient Handout

Header and Footer: removed "interim" designation

Cautions: added diabetic ketoacidosis to bullet about hyperglycemia

Side Effects: updated paragraph for hyperglycemia to include more information about diabetic ketoacidosis

Dosage Guidelines: added BC Cancer protocol UBRAVCAFLV and updated cycle length and dosing regimen

Patient Handout: removed "interim" designation from *Header and Footer*

Docetaxel Monograph

Pharmacokinetics: updated half-life

Eribulin Monograph

Cancer Drug Manual[®]

Cautions: deleted FDA pregnancy category

Supply and Storage: added Natco brand

Zanubrutinib Monograph and Patient Handout

Pharmacokinetics: added information about food effect to *Absorption*

Uses: updated Health Canada approved indications

Interactions: updated Interactions table

Supply and Storage: added new tablet formulation

Dosage Guidelines: added information about crushing/chewing/splitting per dosage form

Patient Handout: added tablet formulation to Introductory bullet and Administration bullet

Revised Documents

The **Nilutamide Monograph** and **Patient Handout** have been retired as nilutamide is no longer available in Canada. **Nilutamide** has been deleted from the **Auxiliary Label List**.

Continuing Education

Family Practice Oncology Network

The Family Practice Oncology Network (FPON) is pleased to announce a webinar session on **Reducing Ovarian Cancer Risk: Discussing Opportunistic Salpingectomy with Patients in Primary Care** with Dr. Gillian Hanley, on Thursday 22 May 2025, 8 to 9 am, as part of the Complimentary Accredited Webinar Series.

By the end of the session, participants will be able to:

- Review current understanding of the pathology of ovarian cancer;
- Explain the rationale for including a salpingectomy during another abdominal surgery;
- Cite the risk reduction for ovarian cancer and the safety data for salpingectomy during another abdominal surgery; and
- Identify patients who would not be eligible for salpingectomy during another abdominal surgery.

For more information and link to registration, visit:

<https://ubccpd.ca/learn/learning-activities/course?eventtemplate=947-fpon-webinar-reducing-ovarian-cancer-risk-discussing-opportunistic-salpingectomy-with-patients-in-primary-care>

Benefit Drug List

New Programs

The following treatment programs have been added to the BC Cancer [Benefit Drug List](#) effective 01 May 2025:

Protocol Title	Protocol Code	Benefit Status
Therapy of Advanced Breast Cancer using Capivasertib and Fulvestrant With or Without LHRH Agonist	UBRAVCAFLV	Restricted
Androgen Deprivation Therapy for Prostate Cancer	GUPADT	Class I
Brentuximab Vedotin in Combination with Doxorubicin , Vincristine , Etoposide and Cyclophosphamide for First Line High Risk Pediatric Hodgkin's Lymphoma	Pediatric	Class I

Deleted Programs

The following programs have been deleted from the BC Cancer [Benefit Drug List](#) effective 01 May 2025:

Protocol Title	Protocol Code	Benefit Status
Therapy for Prostate Cancer using LHRH Agonist (Goserelin or Leuprolide)	GUPLHRH	Class I
Therapy for Advanced Prostate Cancer Using LHRH Antagonist Degarelix	GUPLHRHA	Class I
Non-Steroidal Treatment of Prostate Cancer	GUPNSAA	Class I

Highlights of New & Revised Protocols, PPPOs and Patient Handouts

BC Cancer Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program (CAP) approval are prefixed with the letter **U**.

NEW Protocols, PPPOs and Patient Handouts (*new documents checked* ☒)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
UBRAVCAFLV	Therapy of Advanced Breast Cancer using Capivasertib and Fulvestrant With or Without LHRH Agonist	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
GUPADT	Androgen Deprivation Therapy for Prostate Cancer	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BR Breast				

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BRAJAC	Adjuvant Therapy for Breast Cancer using Doxorubicin and Cyclophosphamide	<i>Contact physician, eligibility, tests and precautions updated</i>	<i>Return appointment orders and tests updated</i>	--
BRAJACT	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Doxorubicin and Cyclophosphamide followed by Paclitaxel	<i>Tests, eligibility and precautions updated</i>	<i>Return appointment orders updated</i>	
BRAJACTG	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Dose Dense Therapy: Doxorubicin and Cyclophosphamide followed by Paclitaxel	<i>Tests clarified, precautions updated</i>	<i>Return appointment orders updated</i>	
BRAJACTT	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Doxorubicin and Cyclophosphamide followed by Paclitaxel and Trastuzumab	<i>Eligibility, tests, dose modifications and precautions updated, minor formatting</i>	<i>Return appointment orders updated</i>	--
BRAJACTTG	Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Dose Dense Therapy: Doxorubicin and Cyclophosphamide Followed by Paclitaxel and Trastuzumab	<i>Tests clarified, precautions updated</i>	<i>Return appointment orders updated, minor formatting</i>	--
BRAJACTW	Neoadjuvant or Adjuvant Therapy for Early Breast Cancer Using Doxorubicin and Cyclophosphamide followed by Weekly Paclitaxel	<i>Eligibility, tests, dose modifications and precautions updated, minor formatting</i>	<i>Return appointment orders and tests updated</i>	--
BRAJDAC	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Cyclophosphamide, Doxorubicin and Docetaxel	<i>Eligibility, tests, dose modifications and precautions updated</i>	<i>Pre-chemo metrics and return appointment orders and tests updated</i>	--
BRAJDC	Neoadjuvant or Adjuvant Therapy for Breast Cancer using Docetaxel and Cyclophosphamide	<i>Tests, treatment, dose modifications and precautions updated, formatting</i>	<i>Pre-chemo metrics, return appointment orders and tests updated, comment re: order of administration deleted, formatting</i>	--
BRAJDCARBT	Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Docetaxel, Carboplatin, and Trastuzumab	<i>Eligibility, tests, treatment, dose modifications and precautions updated, formatting</i>	<i>Pre-chemo metrics, return appointment orders and tests updated</i>	--
BRAJFEC	Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide	<i>Eligibility, tests, dose modifications and precautions updated</i>	<i>Return appointment orders updated</i>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BRAJFCD	Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin, Cyclophosphamide and Docetaxel	<i>Eligibility, tests, treatment, dose modifications and precautions updated</i>	<i>Pre-chemo metrics, return appointment orders and tests updated</i>	--
BRAJFCDT	Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab	<i>Eligibility, tests, treatment, dose modifications and precautions updated</i>	<i>Return appointment orders and tests updated</i>	--
BRAJPEM	Adjuvant Treatment of Resected Triple Negative Breast Cancer using Pembrolizumab	<i>Tests updated, duplicate hyperlinks removed</i>	<i>Tests updated</i>	--
BRAJPNCT	Alternative Neoadjuvant or Adjuvant Therapy for Breast Cancer using Paclitaxel NAB (ABRAXANE), Carboplatin and Trastuzumab	<i>Eligibility, tests, dose modifications, precautions updated, formatting</i>	<i>Return appointment orders and tests updated</i>	--
BRAJTDC	Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Trastuzumab, Docetaxel and Cyclophosphamide	<i>Eligibility, tests, treatment, dose modifications and precautions updated</i>	<i>Pre-chemo metrics, treatment section, return appointment orders and tests updated</i>	--
BRAVPEM	Treatment of Metastatic Breast Cancer using Pembrolizumab	<i>Tests updated</i>	<i>Tests updated</i>	--
BRAVPEM6	Treatment of Metastatic Breast Cancer using 6-Weekly Pembrolizumab	<i>Tests updated</i>	<i>Tests updated</i>	--
BRAVPGC	Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab, Gemcitabine, and Carboplatin	<i>Tests updated</i>	<i>Tests updated</i>	--
BRAVPP	Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab with Paclitaxel	<i>Tests updated</i>	<i>Tests updated</i>	--
BRAVPPN	Palliative Therapy for Metastatic Breast Cancer using Pembrolizumab and Paclitaxel NAB (ABRAXANE)	<i>Tests updated</i>	<i>Tests updated</i>	--
BRAVSG	Palliative Therapy for Metastatic Triple Negative Breast Cancer using Sacituzumab Govitecan	<i>Eligibility, tests, dose modifications and precautions updated, minor formatting</i>	<i>Return appointment orders updated</i>	--
BRLAACD	Treatment of Locally Advanced Breast Cancer using Doxorubicin and Cyclophosphamide followed by Docetaxel	<i>Tests, treatment, dose modifications and precautions updated</i>	<i>Pre-chemo metrics, return appointment orders and tests updated</i>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
BRLAACDT	Treatment of Locally Advanced Breast Cancer using Doxorubicin and Cyclophosphamide followed by Docetaxel and Trastuzumab	<i>Contact physician, eligibility, tests, treatment, dose modifications and precautions updated, formatting</i>	<i>Return appointment orders and tests updated</i>	--
BRLACPNAC	Alternative Neoadjuvant Therapy for Triple Negative Breast Cancer using Carboplatin and Paclitaxel NAB (ABRAXANE) Followed by Doxorubicin and Cyclophosphamide	<i>Eligibility, tests and precautions updated, formatting</i>	<i>Return appointment orders updated</i>	--
BRLACPNACG	Alternative Neoadjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: Carboplatin and Paclitaxel NAB (ABRAXANE) Followed by Doxorubicin and Cyclophosphamide	<i>Tests clarified, precautions updated, formatting</i>	<i>Return appointment orders updated</i>	--
BRLACTWAC	Neoadjuvant Therapy for Triple Negative Breast Cancer Using Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide	<i>Eligibility, tests, dose modifications and precautions updated, formatting</i>	<i>Return appointment orders updated</i>	--
BRLACTWACG	Neoadjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide	<i>Tests clarified, precautions updated</i>	<i>Return appointment orders updated</i>	--
BRLAPNAC	Alternative Neoadjuvant Therapy for Locally Advanced Breast Cancer using Paclitaxel NAB (ABRAXANE) followed by Doxorubicin and Cyclophosphamide	<i>Eligibility, tests, dose modifications and precautions updated</i>	<i>Return orders updated, formatting</i>	--
BRLAPNACG	Alternative Neoadjuvant Therapy for Breast Cancer using Dose Dense Therapy: Paclitaxel NAB (ABRAXANE) followed by Doxorubicin and Cyclophosphamide	<i>Tests clarified, precautions updated</i>	<i>Return appointment orders and tests updated</i>	--
BRLATACG	Neoadjuvant Therapy for Breast Cancer Using Dose Dense Therapy: Paclitaxel Followed by Doxorubicin and Cyclophosphamide	<i>Tests clarified, precautions updated</i>	<i>Return appointment orders updated</i>	--
BRLATWAC	Neoadjuvant Therapy for Locally Advanced Breast Cancer using Weekly Paclitaxel followed by Doxorubicin and Cyclophosphamide	<i>Eligibility, dose modifications and precautions updated, formatting</i>	<i>Return appointment orders updated, formatting</i>	--
BRPCWTAC	Neoadjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab, Weekly Carboplatin and Weekly Paclitaxel, Followed by Doxorubicin and Cyclophosphamide	<i>Eligibility note added, tests and precautions updated</i>	<i>Tests updated</i>	--
BRPCTAC	Neoadjuvant Therapy for Triple Negative Breast Cancer using Pembrolizumab with Carboplatin and Weekly Paclitaxel Followed by Doxorubicin and Cyclophosphamide	<i>Eligibility note added, tests, dose modifications and precautions updated</i>	<i>Tests updated</i>	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
CNMODPCV	Modified PCV Chemotherapy Of Brain Tumours Using Procarbazine, Lomustine (CCNU) and vincristine	<i>Treatment updated</i>	--	--
GI Gastrointestinal				
GIAVDURPG	First-line Palliative Treatment of Advanced Biliary Tract Cancer using Durvalumab, Gemcitabine and Platinum	<i>Tests updated</i>	<i>Tests updated, typo corrected</i>	--
GIAVPEMPG	First-line Palliative Treatment of Advanced Biliary Tract Cancer using Pembrolizumab, Gemcitabine and Platinum	--	<i>Typo corrected</i>	--
GIAVPG	First-line Palliative Chemotherapy for Advanced Gallbladder, Pancreatic Carcinoma, and Cholangiocarcinoma using Gemcitabine and Cisplatin	<i>Tests updated</i>	<i>Tests updated, typo corrected</i>	--
GU Genitourinary				
UGUMCSPDD	Metastatic Castration Sensitive Prostate Cancer using Darolutamide and Docetaxel	<i>Androgen deprivation therapy protocol code updated</i>	--	--
GUPDOCADT	First-Line Treatment of Castration Sensitive, Metastatic Prostate Cancer Using Docetaxel and Androgen Deprivation Therapy	<i>Androgen deprivation treatment options updated</i>	--	--
LY Lymphoma				
LYAVDBV	Treatment of Previously Untreated, Stage III or IV Hodgkin Lymphoma with Doxorubicin, Vinblastine, Dacarbazine and Brentuximab Vedotin	<i>Title, eligibility, exclusions and caution updated, SCNAUSEA hyperlink added, and references updated</i>	--	--
SM Skin & Melanoma				
SMAJNIV	Adjuvant Treatment of Resected Stage III – IV NED Melanoma Using Nivolumab	<i>Eligibility updated and duplicate hyperlinks deleted and formatted</i>	--	--
SMAJNIV4	Adjuvant Treatment of Resected Stage III - IV NED Melanoma Using 4-Weekly Nivolumab	<i>Eligibility updated and duplicate hyperlinks deleted and formatted</i>	--	--
SMAJPEM	Adjuvant Treatment of Resected Stage IIB to IV NED Melanoma Using Pembrolizumab	<i>Eligibility updated and duplicate hyperlinks deleted and formatted</i>	--	--

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

Protocol Code	Protocol Title	Protocol	PPPO	Handout
SMAJPEM6	Adjuvant Treatment of Resected Stage IIB to IV NED Melanoma Using 6-Weekly Pembrolizumab	<i>Eligibility updated and duplicate hyperlinks deleted and formatted</i>	--	--
SMAVIPNI	Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab and Nivolumab	<i>Eligibility and exclusions updated, dose modification formatting</i>	--	--
SMNAPEM	Neoadjuvant-Adjuvant Treatment of Stage IIIB to IV Melanoma Using Pembrolizumab	<i>Eligibility updated</i>	--	--

Resources and Contact Information

Resource	Phone	Email / Toll Free / Fax
Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update		
Systemic Therapy Update Editor	604-877-6000 x 672649	bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275	druginfo@bccancer.bc.ca
Cancer Drug Manual Editor	250-519-5500 x 693742	nbadry@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820	rxchemocert@bccancer.bc.ca
CAP – Compassionate Access Program	604-877-6277	cap_bcca@bccancer.bc.ca fax 604-708-2026
OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement	888-355-0355	oscar@bccancer.bc.ca fax 604-708-2051
Library/Cancer Information	604-675-8003	toll free 888-675-8001 x 8003 requests@bccancer.bc.ca
Library Document Delivery	604-675-8002	requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247	mclin@bccancer.bc.ca
Professional Practice, Nursing	604-877-6000 x 672623	BCCancerPPNAdmin@phsa.ca
Provincial Systemic Therapy Network	604-877-6000 x 672247	ProvincialSystemicOffice@bccancer.bc.ca
BC Cancer – Abbotsford	604-851-4710	toll free 877-547-3777
BC Cancer – Kelowna	250-712-3900	toll free 888-563-7773
BC Cancer – Prince George	250-645-7300	toll free 855-775-7300
BC Cancer – Surrey	604-930-2098	toll free 800-523-2885
BC Cancer – Vancouver	604-877-6000	toll free 800-663-3333
BC Cancer – Victoria	250-519-5500	toll free 800-670-3322
Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca		

Editorial Review Board

Jelena Mucovic, BScPharm (Interim Editor)
 Mario de Lemos, PharmD, MSc(Oncol)
 Jeevan Dosanjh, RN, BScN, MN

Alina Gerrie, MD, MPH, FRCPC
 Alison Pow, BScPharm
 Yuna Jang, RN